JP2007533625A5 - - Google Patents

Download PDF

Info

Publication number
JP2007533625A5
JP2007533625A5 JP2006527336A JP2006527336A JP2007533625A5 JP 2007533625 A5 JP2007533625 A5 JP 2007533625A5 JP 2006527336 A JP2006527336 A JP 2006527336A JP 2006527336 A JP2006527336 A JP 2006527336A JP 2007533625 A5 JP2007533625 A5 JP 2007533625A5
Authority
JP
Japan
Prior art keywords
group
alkyl
carboxy
amino
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006527336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533625A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/010582 external-priority patent/WO2005027882A1/en
Publication of JP2007533625A publication Critical patent/JP2007533625A/ja
Publication of JP2007533625A5 publication Critical patent/JP2007533625A5/ja
Pending legal-status Critical Current

Links

JP2006527336A 2003-09-22 2004-09-21 炎症性及び/又は免疫媒介性の骨量減少の予防及び治療 Pending JP2007533625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50471703P 2003-09-22 2003-09-22
US60/504,717 2003-09-22
PCT/EP2004/010582 WO2005027882A1 (en) 2003-09-22 2004-09-21 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss

Publications (2)

Publication Number Publication Date
JP2007533625A JP2007533625A (ja) 2007-11-22
JP2007533625A5 true JP2007533625A5 (cg-RX-API-DMAC7.html) 2008-01-10

Family

ID=34375537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006527336A Pending JP2007533625A (ja) 2003-09-22 2004-09-21 炎症性及び/又は免疫媒介性の骨量減少の予防及び治療

Country Status (15)

Country Link
US (2) US20100087413A1 (cg-RX-API-DMAC7.html)
EP (2) EP2036548A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007533625A (cg-RX-API-DMAC7.html)
AT (1) ATE416761T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004273610B2 (cg-RX-API-DMAC7.html)
CA (1) CA2539741A1 (cg-RX-API-DMAC7.html)
CY (1) CY1111246T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004018338D1 (cg-RX-API-DMAC7.html)
DK (1) DK1663185T3 (cg-RX-API-DMAC7.html)
ES (1) ES2317029T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ546062A (cg-RX-API-DMAC7.html)
PL (1) PL1663185T3 (cg-RX-API-DMAC7.html)
PT (1) PT1663185E (cg-RX-API-DMAC7.html)
SI (1) SI1663185T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005027882A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005279845A1 (en) * 2004-08-30 2006-03-09 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Inhibition of viruses using RNase H inhibitors
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
DE102005026231A1 (de) * 2005-06-07 2006-12-14 Origenis Ag Peptid-Deformylase (PDF) Inhibitoren 3
EP1864668B1 (en) * 2006-06-01 2012-11-21 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
AU2007271182B2 (en) 2006-07-06 2012-03-15 Glaxo Group Limited Substituted N-phenylmethyl -5-oxo-proline-2-amides as P2X7-receptor antagonists and their methods of use
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
KR101022809B1 (ko) * 2008-02-05 2011-03-17 재단법인서울대학교산학협력재단 면역조절에 의한 캔디다알비칸스 기인성 질환의 치료
JP5637562B2 (ja) * 2008-09-25 2014-12-10 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JP2012041291A (ja) * 2010-08-18 2012-03-01 Institute Of Physical & Chemical Research 歯周病の治療または予防剤
SI2640467T1 (sl) 2010-11-19 2015-04-30 Novartis Ag Kristalinična oblika inhibitorja interakcije MDM2/4 in P53
ITRM20100614A1 (it) * 2010-11-24 2012-05-25 D M G Italia S R L Preparazioni farmaceutiche dell acido 18 beta glicirretico e/o di suoi derivati per infiltrazioni intrarticolari per il trattamento delle artropatie infiammatorie
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
CN105209467B (zh) 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
AU2014272695B2 (en) 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
WO2014191911A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
MX2016006667A (es) 2013-11-21 2016-07-26 Novartis Ag Derivados de pirrolo-pirrolona y su uso como inhibidores.
CN104873521A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其应用
CN104873520A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
CN111386279A (zh) 2017-08-04 2020-07-07 阿德利克斯股份有限公司 用于治疗高钾血症的甘草次酸衍生物
GB201805100D0 (en) * 2018-03-28 2018-05-09 Benevolentai Bio Ltd Treatment of sarcopenic diseases
JP7735185B2 (ja) * 2019-02-07 2025-09-08 アルデリックス, インコーポレイテッド 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体
EP4754084A1 (de) * 2023-07-28 2026-06-10 Symrise AG Heterozyklische verbindungen als physiologische kühlstoffe

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262851A (en) * 1958-06-26 1966-07-26 Biorex Laboratories Ltd Pharmacological compositions containing glycyrrhetinic acid derivative
DE2050072C3 (de) * 1970-10-12 1975-01-30 Inverni Della Beffa S.P.A., Mailand (Italien) Aluminium-tri-3-acetyl-18 betaglycyrrthetinat, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zubereitungen
US3934027A (en) * 1973-05-03 1976-01-20 Pfizer Inc. 18β-Glycyrrhetinic acid amides useful as antiulcer agents
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
GB2261672A (en) * 1991-11-18 1993-05-26 Michael Braden The use of biomaterials for tissue repair
JPH07291857A (ja) * 1994-04-27 1995-11-07 Suntory Ltd グリチルレチン酸化合物を有効成分とする骨疾患の予防及び治療剤
DE19951970A1 (de) * 1999-10-28 2001-05-03 Bionetworks Gmbh Arzneimittel für die Toleranzinduktion
US20050048007A1 (en) * 2000-11-02 2005-03-03 Inobys Ltd. Plaque reducing composition
GB0105772D0 (en) * 2001-03-08 2001-04-25 Sterix Ltd Use
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
IL161154A0 (en) 2001-11-22 2004-08-31 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1461327A1 (en) 2001-11-22 2004-09-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
EP2380899A1 (en) 2002-09-23 2011-10-26 E. I. du Pont de Nemours and Company Isolation and use of ryanodine receptors
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US20030148349A1 (en) * 2003-01-03 2003-08-07 Shyam Ramakrishnan Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
US20220401529A1 (en) Treatment of diseases involving mucin
MX2010005342A (es) Compuestos indola y metodos para tratar el dolor visceral.
US20110071100A1 (en) Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases
JP2016516813A (ja) 抗菌性シデロフォア−アミノペニシリン複合体
EP2124930B1 (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
US20250074907A1 (en) Inhibitors of sars-cov-2
WO2008007367A1 (en) Combination methods of treating cancer
EP1704860B1 (en) Benzamidine derivatives for treatment and prevention of mucositis
EP4335509A3 (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
CN1241573C (zh) 含有丙烯酰司他霉素衍生物以及拓扑异构酶ⅰ和ⅱ抑制剂的药物组合物
CA2643400A1 (en) Camptothecin derivatives and their uses
WO2011152721A1 (en) Derivatives of pantothenic acid and their use for the treatment of malaria
CA2949328A1 (en) Low substituted polymyxins and compositions thereof
US20080293648A1 (en) Compositions and Methods for Cancer Treatment
JP2010500971A5 (cg-RX-API-DMAC7.html)
US20220411409A1 (en) Prodrugs, analogs or derivatives of anthocyanidin as antiviral agents
EP2258370A1 (en) Treatment of malignant diseases
HK1211213B (en) Treatment of diseases involving mucin
HK1095285B (en) Benzamidine derivatives for treatment and prevention of mucositis
JP2008516958A5 (cg-RX-API-DMAC7.html)
HK1058623B (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
HK1058623A1 (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer